Today's Headlines

Imbruvica approved for CLL

FDA expanded the approved use of ibrutinib (Imbruvica, Pharmacyclics and Janssen Biotech) as a single-agent, oral kinase inhibitor for chronic lymphocytic leukemia patients who have received at least 1 previous therapy. » Full article

FDA: Data doesn't support naproxen CV safety claim

After examining the latest research on nonsteroidal anti-inflammatory drugs—specifically whether naproxen carries lower cardiovascular (CV) risks than ibuprofen—an FDA panel has voted down the CV safety claim for naproxen. » Full article

Continuing Education

New CPE series: MTM Considerations for Adult Patients with CVD

Drug Topics kicks off a new CPE series, MTM Considerations for Adult Patients with Cardiovascular Disease, which will include 12 knowledge-based activities worth up to 24 credits. The goal of the first activity, “MTM essentials for cholesterol management,” will empower pharmacists to utilize current understanding of cholesterol management to improve patient care. To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to log in.

Announcement: Welcome to the new user registration process. This new process requires all pharmacists and pharmacy technicians to provide or update their NABP e-Profile ID in order to electronically keep track of CPE credits from ACPE-accredited providers. If you have not done so, you can obtain your NABP e-Profile ID now at www.MyCPEmonitor.net. This profile will enable you to have one login for all the NABP programs and services you will need throughout your career.

EDITOR'S PICK

VIDEO: Drug shortages have big impact on
patient care

Drug shortages remain a serious problem for patient safety, according to newly published results from a survey of pharmacy directors. Nearly half of the responding directors reported adverse events at their facilities resulting from drug shortages — including patient deaths. » Full article

Related Articles

• Under breakthrough therapy designation, FDA approves chronic lymphocytic leukemia drug

• Blood pressure agents, NSAID combo linked to kidney risks

RESOURCES

Drug Watch

Latest Clinical News